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Methods: SiRNA mediated silencing technique was adopted to ensure the depletion of myoferlin 
to reveal the biological function of myoferlin during tumor progression in vivo and in vitro. 
Scoring of immunohistochemically stained patients’ cohort sections was taken up to investigate 
correlation between myoferlin expression and micro-vessel density in patients.  
Results: SiRNA-mediated myoferlin-silencing significantly reduced the volume of BxPC-3 
tumors developed onto the chorioallantoic membrane of fertilized chicken eggs. Intriguingly, 
aside their reduced volume, myoferlin-silenced tumors appeared whitish and exhibited a 
significant decrease of blood vessel density as shown by FITC-conjugated Sambuccus nigra 
agglutinin staining. This observation suggested that, in addition to an inhibition of BxPC-3 cell 
growth after myoferlin silencing, this protein may exhibit a pro-angiogenic activity. Accordingly, 
we next showed that myoferlin-silencing significantly inhibited VEGF-A secretion without 
decreasing VEGF-A gene expression. Immunofluorescence revealed that VEGF-A seemed to 
accumulate in the cytosol at the vicinity of the plasma membrane concomitantly together with 
vesicle like structures, seen by the electron microscopy, in myoferlin depleted cells. Furthermore, 
immunofluorescence techniques showed a colocalization of myoferlin with Sec5/Exoc2, a 
component essential for exocytosis, raising the hypothesis that myoferlin plays a role in VEGF-A 
secretion.  
Conclusions: Our work highlight a new function of myoferlin in pancreatic cancer progression. 
We show that myoferlin is essential for pancreatic cancer cell lines proliferation and tumor 
growth. We also report for the first time myoferlin as a key regulator in VEGF-A secretion by 
controlling the exocytosis of VEGF-A secretory granules in the tumor stroma.  
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Introduction: The search for biomarkers able to detect and evaluate disease such as cancer at an 
early stage, or to predict resistance and response to therapies, has been and remains a major 
challenge. Despite very important progresses in all fields of omics technologies, the success of 
discovery of clinically valuable biomarkers is surprisingly disappointing. Difficult mining of 
secreted proteins in biological fluids poses the first major hurdle, mainly because the 
concentration of interesting proteins in serum or urine is generally very low. The second key 
limitation in the field is the inaccessibility of tissue specimens from early lesions. Those are 
routinely required in their integrity for the complete histological evaluation in the clinical 
routine, leaving no residual material for research.  
Aim: Aim of the study is the discovery of new soluble biomarkers for non invasive diagnosis of 
colorectal cancer and its liver metastasis.  
Methods: Here we present an innovative procedure that we have named EXPEL, which entirely 
overcomes the mentioned limitations. It makes any tissue, regardless of its size, available for 
both omics research and histological investigation.  
Results: Our original device and approach extracts soluble tumor biomarkers and small 
metabolites within few minutes and without altering the tissue morphology. For this purpose a 
small tissue biopsy is incubated in a slightly hypertonic extraction buffer while subjected to 
alternating pressure. Upon extraction the tissue is fixed in formalin and can be used for 
histological analysis. The soluble extract is further prepared for proteomic and metabolomic 
analysis. In a proof of concept study we have extracted and analyzed soluble biomarkers from 
human colorectal carcinoma liver metastases (N=10) as well as primary colorectal tumors 
(N=10). Pathology validation demonstrates that EXPEL procedure does not alter tissue 
morphology or subsequent molecular and clinical tests. The comparison of proteins and 
metabolites identified in tumor lesions with those found in adjacent normal tissues revealed a 
promising group of novel and differentially expressed targets. Their potential usefulness as 
diagnostic or predictive markers is currently being explored.  
Conclusions: The Expel method provides clinicians with a new tool enabling them to non-
destructively discover new biomarkers and preserve precious tissues (like colon polyps) for 
pathology evaluation  
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Introduction: Since 2008, snap frozen tumor tissue and FFPE material is being collected for 
translational and clinical research in Tumorbank@UZA. In this study a total of 87 frozen (-80°C) 
tissue samples from 52 patients with pancreatic cancer and their corresponding uninvolved tissue 
samples (if available) were selected for quality control.  
Aim: We checked if there was a correlation between the RNA quality based on the RIN value 
and pre-analytical variables such as cold ischaemia time and/or sample age. We also evaluated if 
there was a difference in RNA quality between tumour tissue versus reference pancreatic tissue.  
Methods: A trained pathologist evaluated the hematoxilin eosin stainings for the presence of 
tumour and estimation of tumour cell percentage. From the samples that passed this first quality 
control, DNA and RNA was simultaneously isolated using the Qiagen Allprep Micro kit. 
Concentration of nucleic acids was measured by spectophotometry and RNA quality, expressed 
as RNA integrity number (RIN) was measured with the Agilent Bioanalyzer.  
Results: From all selected samples, 70% were acceptable for downstream research after 
evaluation of the HE stainings. Rejection of samples was based on the presence of tumour cells 
in samples that were annotated as reference material and vice versa (16%) or on difficulties in 
assessment of the slide due to presence of artefacts (14%). An overall mean RIN value of 4,2 
reflects that pancreatic tissue is among the most difficult tissues to isolate RNA due to the 
abundant presence of nucleases. In this sample set there was no significant correlation between 
cold ischaemia time or storage time and RNA quality. However, RNA quality was significantly 
higher for tumour tissue as compared to reference tissue (mean RIN respectively 5,1 and 3,2).  
Conclusions: In conclusion, our findings underline the necessity of quality control of banked 
tissue samples in order to find “fit-for-purpose” applications.  
  
